China National Pharmaceutical Group's Independent Director Chen Jiannan's 2025 Annual Performance Report Released, Focusing on Risk Prevention and Control and the Rights of Small and Medium Shareholders

Log in to the Sina Finance app, search 【disclosure information】, and view more assessment tier details

Fangfang Network Data China National Pharmaceutical Group Consistent Pharmaceutical Co., Ltd. (abbreviated as “Guoyi Consistent”) recently released its annual report on the work of independent director Chen Jiannan for 2025. The report shows that Chen Jiannan has served as an independent director on the Company’s tenth board of directors since February 2025. During the 2025 fiscal year, he performed his duties diligently, actively safeguarded the legitimate rights and interests of the Company and all its shareholders, especially those of small and medium-sized investors.

In terms of overall duty performance, during the reporting period Chen Jiannan personally attended all board meetings that he was required to attend (a total of 10 times, including 4 in-person meetings and 6 via communication) and shareholders’ meetings (2 times), with no instances of absence. As the convener of the board’s Remuneration and Performance Evaluation Committee and a member of the Nomination Committee, he convened and presided over 2 meetings of the Remuneration and Performance Evaluation Committee, attended 2 Nomination Committee meetings, and participated in the independent directors’ special meetings. He gained a deep understanding of the Company’s operations and internal control status through reviewing materials, conducting on-site investigations (including visits to the Guangzhou Huadu SPD project, the Shenzhen logistics Liguang warehouse, and Shanghai Guoduo Pharmacy stores, etc.), and communicating with senior management and the annual audit accounting firm. His cumulative on-site working time totaled 15 days.

Regarding the key matters he focused on in fulfilling his duties, Chen Jiannan conducted careful review of and provided comments on multiple core resolutions. These included examining and approving the Company’s 2025 expected额度 for daily related-party transactions, focusing on their fairness and independence; examining the appointment of the auditing firm for 2025; recognizing the financial information in the Company’s quarterly reports, annual report, and internal control evaluation report; examining the resolution on the Company’s provision for asset impairment reserves, assessing its prudence and authenticity; and reviewing the Company’s compensation arrangements and schemes for its directors, supervisors, and senior management for 2025. In addition, he paid attention to the timeliness and accuracy of the Company’s performance forecast announcements and performance express reports.

In the report, Chen Jiannan emphasized that his performance of duties has always focused on safeguarding the legitimate rights and interests of small and medium-sized shareholders. By participating in meetings, performance briefings, and other activities, he listened to the demands of small and medium-sized shareholders, and urged the Company to comply with standardized information disclosure to protect all shareholders’ right to be informed. By maintaining communication with internal audit and the accounting firm, he supervised the objectivity and fairness of financial reporting and audit work.

Overall, in 2025 Chen Jiannan strictly complied with relevant laws and regulations, actively played the supervisory and advisory role of an independent director, focused on risk prevention and control such as the Company’s accounts receivable and external investments, and worked to promote the scientific nature of the Company’s board decision-making, while safeguarding the Company’s overall interests and its image in the capital market. He stated that in 2026 he will continue to fulfill his duties diligently and conscientiously and perform his responsibilities as an independent director.

A wealth of information and precise interpretation—available on the Sina Finance app